SCHEMBL4937141

SCHEMBL4937141

CCOc1ccc(C=CC(C)=O)cc1OC

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 3/20 0.81
APP P05067 3/20 0.73
MAPT P10636 2/20 0.70
NPC1 O15118 1/20 0.70
RAB9A P51151 1/20 0.70
KDM4E B2RXH2 4/20 0.63
LMNA P02545 1/20 0.62
NFE2L2 Q16236 1/20 0.61
ALDH1A1 P00352 3/20 0.60
HPGD P15428 2/20 0.60
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
PTGES O14684 1/20 0.60
ALOX15 P16050 1/20 0.59
MAPK1 P28482 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
HSD17B10 Q99714 1/20 0.59
PDE4A P27815 1/20 0.58
PDE4B Q07343 1/20 0.58
PDE4C Q08493 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4937130 1.00 FDPS (0.81) FDPSAPPMAPTNPC1RAB9A
SCHEMBL4937232 0.94 FDPS (0.72) FDPSAPPMAPTNPC1RAB9A
SCHEMBL4937226 0.94 FDPS (0.72) FDPSAPPMAPTNPC1RAB9A
SCHEMBL3690896 0.88 KDM4E (0.80) FDPSMAPTNPC1RAB9AKDM4E
SCHEMBL15045789 0.88 MAPT (0.70) FDPSAPPMAPTNPC1RAB9A
SCHEMBL3690899 0.88 KDM4E (0.80) FDPSMAPTNPC1RAB9AKDM4E
SCHEMBL30966315 0.88 KDM4E (0.80) FDPSMAPTNPC1RAB9AKDM4E
SCHEMBL4937166 0.88 FDPS (0.79) FDPSAPPKDM4ENFE2L2ALDH1A1
SCHEMBL4937158 0.88 FDPS (0.79) FDPSAPPKDM4ENFE2L2ALDH1A1
SCHEMBL5598627 0.87 FDPS (0.79) FDPSAPPMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1783115-B1 ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE INST MATERIA MEDICA CAMS (CN) 2016-07-13 EP disclosed
US-8524744-B2 preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc. INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2013-09-03 US disclosed
US-20080221106-A1 Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2008-09-11 US disclosed
CN-101146772-A Arylamine ketone compound, synthesis method thereof, pharmaceutical composition containing arylamine ketone compound and application of arylamine ketone compound INST MATERIA MEDICA CAMS (CN) 2008-03-19 CN disclosed
EP-1783115-A1 ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221106-A1 Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use AHR, KYNU, AADAC FDPS 1368/4885APP 245/4885MAPT 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.